Barclays PLC Has $1.49 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)

Barclays PLC increased its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 310.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 52,301 shares of the company’s stock after buying an additional 39,567 shares during the period. Barclays PLC owned 0.19% of Castle Biosciences worth $1,491,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Quest Partners LLC increased its stake in shares of Castle Biosciences by 54.4% during the 3rd quarter. Quest Partners LLC now owns 4,318 shares of the company’s stock worth $123,000 after purchasing an additional 1,522 shares during the last quarter. US Bancorp DE grew its holdings in Castle Biosciences by 1,889.2% during the third quarter. US Bancorp DE now owns 4,615 shares of the company’s stock worth $132,000 after purchasing an additional 4,383 shares during the period. Point72 DIFC Ltd acquired a new position in shares of Castle Biosciences during the 3rd quarter worth approximately $140,000. Assetmark Inc. raised its position in shares of Castle Biosciences by 16.8% in the third quarter. Assetmark Inc. now owns 5,212 shares of the company’s stock valued at $149,000 after purchasing an additional 748 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in Castle Biosciences by 64.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,335 shares of the company’s stock worth $152,000 after acquiring an additional 2,093 shares during the last quarter. 92.60% of the stock is owned by institutional investors.

Castle Biosciences Stock Performance

Castle Biosciences stock opened at $26.83 on Friday. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02. The stock has a market cap of $751.43 million, a PE ratio of 134.16 and a beta of 0.92. Castle Biosciences, Inc. has a 12-month low of $16.97 and a 12-month high of $35.84. The business’s 50-day moving average price is $30.49 and its two-hundred day moving average price is $27.41.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.14. The company had revenue of $85.78 million for the quarter, compared to analyst estimates of $78.55 million. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. During the same period in the previous year, the firm posted ($0.26) EPS. As a group, analysts expect that Castle Biosciences, Inc. will post 0.34 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Daniel Bradbury sold 7,867 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $29.44, for a total value of $231,604.48. Following the completion of the transaction, the director now owns 5,700 shares of the company’s stock, valued at $167,808. This represents a 57.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Derek J. Maetzold sold 9,364 shares of Castle Biosciences stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $28.34, for a total transaction of $265,375.76. Following the sale, the insider now owns 84,762 shares in the company, valued at approximately $2,402,155.08. This represents a 9.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 35,549 shares of company stock valued at $1,079,871. 7.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on CSTL. KeyCorp lifted their target price on Castle Biosciences from $28.00 to $36.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Canaccord Genuity Group raised their price objective on Castle Biosciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, October 29th. Scotiabank increased their target price on Castle Biosciences from $37.00 to $44.00 and gave the stock a “sector outperform” rating in a report on Wednesday, November 6th. BTIG Research boosted their price target on Castle Biosciences from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Finally, Robert W. Baird increased their price objective on shares of Castle Biosciences from $37.00 to $39.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Castle Biosciences presently has a consensus rating of “Buy” and a consensus target price of $39.71.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.